Trabectedin Combined With Durvalumab (Human Monoclonal Antibody) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. (TRAMUNE) .
ClinicalTrials Identifier: NCT03085225
Updated: 2017_04_25
Descriptive Information :
Brief title :
Trabectedin Combined With Durvalumab in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas.
Official title :
Trabectedin Combined With Durvalumab (MEDI4736) in Patients With Advanced Pretreated Soft-tissue Sarcomas and Ovarian Carcinomas. A Phase Ib Study.
Brief summary :
A Phase Ib trial study of trabectedin when prescribed in combination with durvalumab in locally advanced/unresectable soft-tissue sarcoma and ovarian carcinomas.
Detailed description :
This is a Multicenter, Prospective Phase Ib Trial based on a dose escalation study design (3+3 traditional design) assessing three dose levels of Trabectedin given with Durvalumab ,followed by two expansion cohorts once the MTD is established.Administrative Data :
Organization name : Institut Bergonié
Organization study ID : IB2016-02
Sponsor : Institut Bergonié
Collaborator : AstraZeneca
Collaborator : PharmaMar
...